stage III melanoma
Information
- Disease name
- stage III melanoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03719131 | Active, not recruiting | Phase 2 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | June 5, 2019 | September 13, 2024 |
| NCT05079113 | Active, not recruiting | Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting | October 1, 2019 | April 2025 | |
| NCT03200847 | Active, not recruiting | Phase 1/Phase 2 | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | October 31, 2017 | August 2024 |
| NCT00019890 | Completed | Phase 2 | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma | March 2007 | |
| NCT00030615 | Completed | Phase 1 | Decitabine in Treating Patients With Advanced Solid Tumors | December 2001 | |
| NCT00074308 | Completed | Phase 1/Phase 2 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | October 2003 | July 2009 |
| NCT00089362 | Completed | Phase 1 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | July 2004 | |
| NCT00119249 | Completed | Phase 2 | Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | June 2005 | |
| NCT00217542 | Completed | Phase 1 | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery | July 2005 | |
| NCT00349206 | Completed | Phase 1 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | April 2006 | February 2012 |
| NCT00450255 | Completed | Phase 2 | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | June 2007 | January 2011 |
| NCT01107665 | Completed | Phase 2 | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma | August 2010 | February 2018 |
| NCT00003647 | Completed | Phase 3 | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma | July 1998 | September 2002 |
| NCT00003789 | Completed | Phase 3 | Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg | March 1999 | |
| NCT00003646 | Completed | Phase 2 | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma | August 1998 | May 2002 |
| NCT01376713 | Completed | Phase 2 | Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma | June 2011 | May 2015 |
| NCT01726738 | Completed | Phase 2 | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | April 4, 2013 | September 17, 2020 |
| NCT02073123 | Completed | Phase 1/Phase 2 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | July 2014 | July 3, 2019 |
| NCT02306850 | Completed | Phase 2 | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | January 2015 | June 8, 2018 |
| NCT02676869 | Completed | Phase 1 | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma | April 2016 | December 2019 |
| NCT02794636 | Completed | Interferon Toxicities in Melanoma Treatment | May 2014 | November 2015 | |
| NCT04059224 | Completed | Phase 2 | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma | January 28, 2019 | June 30, 2023 |
| NCT03385486 | Recruiting | Phase 1 | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors | June 2, 2019 | December 2024 |
| NCT01026051 | Terminated | Phase 2 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | October 2010 | July 2012 |
| NCT00082875 | Terminated | Phase 2 | Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma | March 2004 | |
| NCT00087386 | Terminated | Phase 2 | Tanespimycin in Treating Patients With Stage III-IV Melanoma | June 2004 | |
| NCT00945269 | Terminated | Phase 1/Phase 2 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | July 2009 | January 2011 |
| NCT01875653 | Terminated | Phase 3 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | October 2014 | January 2016 |
| NCT01168050 | Unknown status | Phase 2 | Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. | July 2010 | December 2013 |
| NCT01851408 | Withdrawn | Phase 2 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | April 2006 | February 2012 |
| NCT04703426 | Withdrawn | Phase 2 | Sargramostim (GM-CSF) + PD-1 | April 16, 2021 | June 9, 2025 |